

RESOURCES

PEOPLE

FeRx (San Diego, CA) has named **Vicente Anido Jr.** to its board of directors. Most recently, he was president and CEO of CombiChem, which was sold to DuPont Pharmaceuticals last year.

Wolfgang Berthold has been appointed senior vice president of biopharmaceutical sciences at IDEC Pharmaceuticals (San Diego, CA). Dr. Berthold comes to IDEC from Hoffmann-La Roche, where he was vice president of biopharmaceuticals and served as international advisor for all Roche pharmaceutical biotechnology projects in development.

Quintiles Transnational Corp. (Research Triangle Park, NC) has named **James Bierman** chief financial officer, succeeding **Rachel Selisker**, who remains as a consultant. Mr. Bierman joined Quintiles in 1998 and has been responsible for the company's merger, acquisition, and alliance activity.

Sally D. Bolmer has joined Human Genome Sciences (Rockville, MD) as vice president, regulatory affairs and as a member of its pharma committee. She joins HGSI from Centocor, where she was most recently executive director, worldwide regulatory affairs.

Biogen (Cambridge, MA) has named **Nadine Cohen** as director, regulatory affairs. Dr. Cohen joins Biogen from the Massachusetts Biologics Laboratories, where she was senior director of quality control and technical services. In addition, **John McCoy** has been named director, molecular technologies. He was previously senior director of molecular biology and gene expression at Genetics Institute.

BioInvent Therapeutic (Lund, Sweden) has announced the appointment of **Goeran Conradson** as vice president, business development. Previously, he was European marketing and sales manager at Pharmacia Biotech.

Ino Cooijmans has been named vice president and CFO of Pharming (Leiden, The Netherlands). Previously, he was director of finance for Centocor BV. In addition, Pharming has appointed **Philippe van Holle** vice president and managing director of its business unit for orphan products.

Stephen R. Davis has been promoted to senior vice president and chief business officer of Neurogen (Branford, CT). Mr. Davis joined the company in 1994 as vice president and CFO from the law firm of Milbank, Tweed, Hadley & McCloy.

Eligix (Medford, MA) has named **James R. Fitzgerald, Jr.** as senior vice president, finance and operations, and CFO. Most recently he served as vice president, treasurer, and CFO at ArQule.

Julia P. Gregory has been selected as Lexicon Genetics' (The Woodlands, TX) executive vice president and CFO. She is the former head of investment banking and head of



the life science practice at Punk, Ziegel & Company in New York. Lexicon also announced the appointment of **James R. Piggott** as senior vice president of pharmaceutical biology. He was most recently senior vice president-research biology at Zymo-Genetics.

ArQule (Woburn, MA) has announced the appointments of **David Hastings** as CFO and **Sheila DeWitt** as director, business development. Mr. Hastings served most recently as vice president, corporate controller at Genzyme, and Dr. DeWitt joins ArQule from Orchid Biocomputer, where she was senior director of business development.

A. Grant Heidrich, III, has been elected chairman of the board of Tularik (S. San Francisco, CA). Since 1984, he has been a general partner with Mayfield Fund, Tularik's lead and founding investor, and has served on the board for nine years. Former chairman Robert Swanson recently passed away after a long fight against cancer.

ACLARA BioSciences (Mountain View, CA) has announced the appointment of **Eric S. Lander** to its board of directors. Dr. Lander is director of the Whitehead/MIT Center for Genome Research, a member of the Whitehead Institute for Biomedical Research, and founder and chairman of Millennium Pharmaceuticals.

Lewis J. Shuster, a member of the Invitrogen's (San Diego, CA) board of directors since 1998, has been appointed COO. Most recently, he was president and COO of Pharmacopeia Laboratories.

Randy Thurman has joined CuraGen's (New Haven, CT) board of directors. He is the founder, chairman, and CEO of Strategic Reserves International and from 1993 to 1996, served as president and CEO of Rhône-Poulenc Rorer Pharmaceuticals.